CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 368 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02008682
NCT02008682Phase 4Completed
CompareCT.gov

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)

Novo Nordisk A/S·interventional·Posted Dec 11, 2013·Updated Mar 9, 2017

In Brief

A Phase 4 clinical trial evaluating liraglutide and sitagliptin for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 368 participants across 25 sites.

Detailed Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Eligible subjects will continue their metformin background treatment during the trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 11, 2013
Enrollment StartDec 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.6 years ago

Interventions

liraglutidedrug

Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.

sitagliptindrug

Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.